ResMed Posts Strong Q4 Revenue But Issues Cautious 2027 Outlook Amid Competition

Key Facts

At a time when investors are scrutinizing the sustainability of growth in the medical device sector, ResMed reported strong Q4 fiscal 2026 results driven by robust demand for its sleep apnea portfolio. According to reports, revenue increased 9% to $1.5 billion, supported by growth in device and mask sales across the Americas. However, the company issued fiscal 2027 revenue guidance of $5.75 billion to $5.85 billion, falling short of the $5.92 billion anticipated by Wall Street analysts.

The company is navigating both operational and competitive headwinds, as market data highlights risks from the potential return of Philips Respironics to the U.S. market. This re-entry could challenge ResMed's recent market dominance in sleep and breathing health. Furthermore, the suspension of Astral ventilator sales following a Class I FDA recall remains a near-term concern. Despite these factors, some research firms have upgraded the stock and raised price targets to $262, citing continued market leadership in obstructive sleep apnea treatments.

Regarding market levels, updated price data for RSMDF was unavailable at the close of September 19, 2026, leaving qualitative outlooks as the primary driver for investors. Market participants are closely watching for further regulatory updates on the Astral platform or competitive announcements. While the upcoming economic calendar lacks direct sector catalysts, broader sentiment remains influenced by recent data such as the NY Empire State Manufacturing Index, which printed at 7.6 on September 15.